Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Bristol-Myers Squibb Recalls Mislabeled Anticoagulant Drug



Bottles of the anticoagulant drug labeled as 5mg were found to contain 2.5 mg tablets.

Share this!

June 19, 2017 | by Sarah Hand, M.Sc.

Pharmaceutical company Bristol-Myers Squibb has recalled one lot of 5 mg Eliquis (apixaban) tablets after the batch was identified as being mislabeled. Bottles of the anticoagulant drug labeled as 5mg were found to contain 2.5 mg tablets.

The error was identified after a customer complained about the mislabeled bottle. Wholesale and retail pharmacies across the US could have this batch in stock, which was distributed in February of this year.

“Patients should not stop taking Eliquis without consulting with their physician,” said a press release issued by Bristol-Myers Squibb. “Patients who are prescribed Eliquis 5 mg for an irregular heartbeat (atrial fibrillation) and take an Eliquis 2.5 mg tablet instead, particularly for a prolonged period, would have an increased probability of stroke, a moving blood clot, or death.”

Eliquis is a blood thinner used to decrease the risk of blood clots and stroke in patients with atrial fibrillation and those who have recently undergone hip or knee replacement surgery. Patients prescribed 5mg Eliquis who unknowingly take the 2.5 mg tablets could be at an increased risk of a growing or moving blood clot and stroke.

While underdosing of the anticoagulant could lead to potentially life-threatening side effects, the company said that no illness related to the mislabeled Eliquis have been reported. Fortunately, the two doses of medication show obvious differences including colour, size and share.

The 2.5 mg tablet is yellow and round with the number “893” imprinted on one side, and “2½” on the other side. In contrast, the 5 mg tablet is pink and oval with “894” imprinted on one side and “5” on the other.

“Patient safety is our first priority,” said the press release. “Bristol-Myers Squibb has notified wholesalers and pharmacies to arrange for return and replacement of any recalled product.”

Patients with lot number HN0063 are being encouraged to contact their physician and the Bristol-Myers Squibb Customer Information Center for details on how to exchange the product. They should also report any adverse events they’ve experienced that may be related to taking mislabeled Eliquis.

Keywords:  Recall, Drug Safety, Anticoagulant


Share this with your colleagues!

Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News

Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News

Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


One Patient’s Perspective on Clinical Trials


Planning and Conducting Trials of the Latest Immunotherapies

ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation

Medical Devices: Reviewing Regulatory Changes in the US and EU

Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.